Clinical Trial Update: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating talazoparib in combination with androgen deprivation therapy and abiraterone for castration-sensitive prostate cancer, current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Talazoparib (talazoparib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING